Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Strategic Investment Advisors MI

Strategic Investment Advisors MI reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 81.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,443 shares of the biopharmaceutical company’s stock after selling 47,213 shares during the quarter. Strategic Investment Advisors MI’s holdings in Gilead Sciences were worth $965,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of GILD. nVerses Capital LLC purchased a new position in shares of Gilead Sciences during the 3rd quarter worth $25,000. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences during the 4th quarter valued at about $29,000. Valued Wealth Advisors LLC boosted its holdings in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares during the period. Strategic Investment Solutions Inc. IL purchased a new position in Gilead Sciences during the 2nd quarter valued at about $33,000. Finally, Friedenthal Financial purchased a new position in Gilead Sciences during the 3rd quarter valued at about $50,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the sale, the insider now owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 456,234 shares of company stock worth $42,130,461. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Stock Up 0.2 %

Gilead Sciences stock opened at $93.07 on Monday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The company has a market cap of $115.99 billion, a PE ratio of 1,034.11, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18. The stock’s 50 day moving average price is $91.74 and its 200 day moving average price is $84.98.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.29 earnings per share. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were given a dividend of $0.77 per share. The ex-dividend date was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.31%. Gilead Sciences’s payout ratio is 3,422.22%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on GILD. Oppenheimer raised their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Piper Sandler increased their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Wolfe Research began coverage on Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target on the stock. UBS Group increased their price target on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Finally, Mizuho increased their price target on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $97.96.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.